Company profile
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ: CRBP · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
45DFH 48DQ 58GM 6SS 56
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, filing timeliness · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$78.5M
Employees
36
as of 2026-08-18
Market cap
$190.5M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02022
Net income-$78.5M-$78.5M2025
Operating income-$85.3M-$85.3M2025
Total assets$168.2M$168.2M2025
Liabilities$20.7M$20.7M2025
Equity$147.5M$147.5M2025
Revenue trend
FY2017 – FY2022 · USD
FY17
FY17
FY17
FY19
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Corbus Pharmaceuticals Holdings, Inc.’s revenue?
Corbus Pharmaceuticals Holdings, Inc. booked $0 in FY2022 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Capricor Therapeutics, Inc.57CMinerva Neurosciences, Inc.38DEupraxia Pharmaceuticals Inc.42DImmuneering Corporation43DNkarta, Inc.47DOnKure Therapeutics, Inc.46DNeighbors
Norfolk →Key facts
CEOYuval Cohen
SectorHealthcare
IndustryBiotechnology
HeadquartersNorwood, MA
ExchangeNASDAQ: CRBP
Employees36
IPO date2014-10-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.